Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections
- PMID: 32304146
- PMCID: PMC7264739
- DOI: 10.1002/ddr.21672
Response to recent commentaries regarding the involvement of angiotensin-converting enzyme 2 (ACE2) and renin-angiotensin system blockers in SARS-CoV-2 infections
Comment on
-
Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics.Drug Dev Res. 2020 Aug;81(5):537-540. doi: 10.1002/ddr.21656. Epub 2020 Mar 4. Drug Dev Res. 2020. PMID: 32129518 Free PMC article.
-
Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?Lancet Respir Med. 2020 Apr;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8. Epub 2020 Mar 11. Lancet Respir Med. 2020. PMID: 32171062 Free PMC article. No abstract available.
References
-
- Chappell, M. C. , Pirro, N. T. , Sykes, A. , & Ferrario, C. M. (1998). Metabolism of angiotensin‐(1‐7) by angiotensin‐converting enzyme. Hypertension, 31(1 Pt 2), 362–367. - PubMed
-
- Dales, N. A. , Gould, A. E. , Brown, J. A. , Calderwood, E. F. , Guan, B. , Minor, C. A. , … Patane, M. A. (2002). Substrate‐based design of the first class of angiotensin‐converting enzyme‐related carboxypeptidase (ACE2) inhibitors. Journal of the American Chemical Society, 124(40), 11852–11853. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous